Gland Pharma delivered exceptional Q4 FY26 results with consolidated net profit jumping 96.57% year-on-year to ₹366.68 crore. According to reports from Business Standard, the company achieved revenue growth of 22.31% to ₹1,742.79 crore compared to Q4 FY25. Profit before tax stood at ₹505.80 crore, representing a significant increase from ₹288.33 crore recorded in the previous year. The company's consolidated EBITDA reached ₹614.46 crore with a margin of 29.44%, registering 60% year-on-year growth. For the full year FY26, net profit rose 47.07% to ₹1,027.32 crore compared to ₹698.53 crore in FY25, while sales increased 14.50% to ₹6,430.65 crore from ₹5,616.50 crore in the previous year.
As reported by Business Standard, revenue from the USA aggregated to ₹980.7 crore, up 25.44% year-on-year, while Europe revenue added up to ₹381.4 crore, growing 36% year-on-year. The rest of the world revenue was ₹254.9 crore, up 6% year-on-year. Sales in Canada, Australia and New Zealand were ₹58.8 crore, down 2% year-on-year, while India sales were ₹67 crore, up 28% year-on-year. The company's adjusted EBITDA margin of 26% for FY26 was supported by robust growth in the CDMO segment and new product launches.
According to Business Standard, R&D expenses stood at ₹50.6 crore in Q4 FY26, accounting for 4% of base business revenue, primarily directed toward complex product development and filings. During the quarter, the company launched five molecules in the US, including Dalbavancin and Brimonidine, taking total US launches in FY26 to 31 products. The company made eight ANDA filings and received 11 approvals in Q4 FY26, while FY26 saw 24 filings and 28 approvals, taking cumulative US ANDA filings to 388 (337 approved and 51 pending). For the full year, operating profit margin improved to 25.34% from 22.59% in the previous year.
As reported by Business Standard, under co-development partnerships, 15 products are in development, including seven 505(b)(2) and eight ANDAs, with commercialization expected from FY28. The company advanced its Ready-to-Use (RTU) bag portfolio with 21 filings, 18 approvals, and 11 products under development, addressing an estimated US market opportunity of $634 million. In the GLP-1 and insulin analog segment, the company launched Liraglutide in the US with pen/cartridge capacity at 140 million units per annum. Additionally, a new CDMO contract was signed for a complex nano drug delivery system-based injectable in oncology. The in-house complex pipeline continues to strengthen with six products already launched and three awaiting approval, with complex injectables expected to remain a key long-term growth driver.
According to Business Standard, the board has recommended a final dividend of ₹20 per equity share of face value ₹1 each (2000%) for FY26. If approved, the dividend will be paid within 30 days from the date of the 48th Annual General Meeting. The record date for determining eligible shareholders has been fixed as Tuesday, August 11, 2026. Shares of Gland Pharma fell 1.80% to end at ₹1,861 on the BSE following the results announcement. However, recent market data shows the stock has gained for a third straight session, trading at ₹1,913.1, up 2.27% on the day, with the Nifty Pharma index rising 9.03% in the last month.
